Associated Papers
Phase II study of nivolumab in patients with genetic alterations in DNA damage repair and response who progressed after standard treatment for metastatic solid cancers (KM-06).
Kim JW et al.
Journal for Immunotherapy of Cancer, 2024
38485184 (PubMed )
Supplement: jitc-2023-008638supp001.pdf
Select a paper to view details